| Market Cap | 11.96M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -12.28M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 3.00% |
| Sales | 3.43M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -10.00% |
| Dividend | N/A | Price/Book | 0.40 | EPS next 5Y | - | 52W High Chg | -57.00% |
| Recommedations | 1.50 | Quick Ratio | 4.07 | Shares Outstanding | 8.73M | 52W Low Chg | 15.00% |
| Insider Own | - | ROA | -28.94% | Shares Float | 2.54B | Beta | 0.77 |
| Inst Own | 1.00% | ROE | -53.72% | Shares Shorted/Prior | 90.28K/26.39K | Price | 2.91 |
| Gross Margin | 93.53% | Profit Margin | - | Avg. Volume | 4,925 | Target Price | 7.00 |
| Oper. Margin | -348.40% | Earnings Date | - | Volume | 720 | Change | 0.69% |
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
| Benchmark | Speculative Buy | Mar 7, 24 |
| Ladenburg Thalmann | Buy | Jun 5, 23 |